High COVID-19 transmission potential associated with re-opening universities can be mitigated with layered interventions.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
17 08 2021
Historique:
received: 20 09 2020
accepted: 21 07 2021
entrez: 18 8 2021
pubmed: 19 8 2021
medline: 26 8 2021
Statut: epublish

Résumé

Controlling COVID-19 transmission in universities poses challenges due to the complex social networks and potential for asymptomatic spread. We developed a stochastic transmission model based on realistic mixing patterns and evaluated alternative mitigation strategies. We predict, for plausible model parameters, that if asymptomatic cases are half as infectious as symptomatic cases, then 15% (98% Prediction Interval: 6-35%) of students could be infected during the first term without additional control measures. First year students are the main drivers of transmission with the highest infection rates, largely due to communal residences. In isolation, reducing face-to-face teaching is the most effective intervention considered, however layering multiple interventions could reduce infection rates by 75%. Fortnightly or more frequent mass testing is required to impact transmission and was not the most effective option considered. Our findings suggest that additional outbreak control measures should be considered for university settings.

Identifiants

pubmed: 34404780
doi: 10.1038/s41467-021-25169-3
pii: 10.1038/s41467-021-25169-3
pmc: PMC8371131
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5017

Subventions

Organisme : Medical Research Council
ID : MR/V038613/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/5
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC/PC/19067
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 217509/Z/19/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19067/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19067
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V028545/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 208806/Z/17/Z
Pays : United Kingdom

Informations de copyright

© 2021. The Author(s).

Références

PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Am J Infect Control. 2003 Oct;31(6):364-70
pubmed: 14608304
Science. 2020 May 8;368(6491):
pubmed: 32234805
Lancet Infect Dis. 2021 Jun;21(6):e163-e169
pubmed: 33301725
Nat Commun. 2021 Jun 15;12(1):3643
pubmed: 34131124
J Infect. 2021 Jul;83(1):104-111
pubmed: 33933527
Lancet Respir Med. 2020 May;8(5):446-447
pubmed: 32224304
Clin Infect Dis. 2021 Jun 1;72(11):1992-1999
pubmed: 32322889
Clin Infect Dis. 2021 Jul 30;73(Suppl 2):S138-S145
pubmed: 33045075
J Am Coll Health. 2001 Sep;50(2):57-66
pubmed: 11590984
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200276
pubmed: 34053268
Vaccine. 2011 May 17;29(22):3883-7
pubmed: 21447315
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200280
pubmed: 34053251
BMC Infect Dis. 2009 Jan 20;9:5
pubmed: 19154612
Math Biosci Eng. 2020 Dec 14;18(1):551-563
pubmed: 33525107
J Am Coll Health. 2020 Oct;68(7):688-697
pubmed: 31084526
Proc Biol Sci. 2013 Jun 26;280(1765):20131037
pubmed: 23804621
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Emerg Infect Dis. 2020 Nov;26(11):2598-2606
pubmed: 33035448
Epidemiol Infect. 1999 Oct;123(2):185-92
pubmed: 10579436
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):
pubmed: 33431650
Clin Infect Dis. 2020 Dec 17;71(10):2752-2756
pubmed: 32463076
JAMA Netw Open. 2020 Jul 1;3(7):e2016818
pubmed: 32735339
J R Soc Interface. 2012 Nov 7;9(76):2826-33
pubmed: 22718990
Sci Rep. 2021 Jun 3;11(1):11728
pubmed: 34083593
BMJ. 2015 Feb 19;350:h810
pubmed: 25697392

Auteurs

Ellen Brooks-Pollock (E)

Bristol Veterinary School, University of Bristol, Langford, Bristol, UK. Ellen.Brooks-Pollock@bristol.ac.uk.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Ellen.Brooks-Pollock@bristol.ac.uk.

Hannah Christensen (H)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Adam Trickey (A)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Gibran Hemani (G)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Emily Nixon (E)

School of Biological Sciences, University of Bristol, Bristol, Bristol, UK.

Amy C Thomas (AC)

Bristol Veterinary School, University of Bristol, Langford, Bristol, UK.

Katy Turner (K)

Bristol Veterinary School, University of Bristol, Langford, Bristol, UK.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Adam Finn (A)

Bristol Children's Vaccine Centre, University of Bristol, Bristol, Bristol, UK.

Matt Hickman (M)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Caroline Relton (C)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Leon Danon (L)

Department of Engineering Mathematics, University of Bristol, Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH